[go: up one dir, main page]

SG11202103133QA - Pyrazole derivatives as h4 antagonist compounds - Google Patents

Pyrazole derivatives as h4 antagonist compounds

Info

Publication number
SG11202103133QA
SG11202103133QA SG11202103133QA SG11202103133QA SG11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA
Authority
SG
Singapore
Prior art keywords
pyrazole derivatives
antagonist compounds
antagonist
compounds
pyrazole
Prior art date
Application number
SG11202103133QA
Inventor
Giles Albert Brown
Miles Stuart Congreve
Barry John Teobald
Charlotte Fieldhouse
Nigel Alan Swain
Mark Pickworth
Giovanni Bottegoni
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of SG11202103133QA publication Critical patent/SG11202103133QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202103133QA 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds SG11202103133QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1817047.2A GB201817047D0 (en) 2018-10-19 2018-10-19 H4 antagonist compounds
PCT/GB2019/052997 WO2020079457A1 (en) 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds

Publications (1)

Publication Number Publication Date
SG11202103133QA true SG11202103133QA (en) 2021-05-28

Family

ID=64453795

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103133QA SG11202103133QA (en) 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds

Country Status (12)

Country Link
US (2) US12234227B2 (en)
EP (1) EP3867248A1 (en)
JP (1) JP7532353B2 (en)
KR (1) KR20210079318A (en)
CN (1) CN113272297B (en)
AU (1) AU2019360428B2 (en)
BR (1) BR112021007372A2 (en)
CA (1) CA3116628A1 (en)
GB (1) GB201817047D0 (en)
MX (1) MX2021004280A (en)
SG (1) SG11202103133QA (en)
WO (1) WO2020079457A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
GB202019667D0 (en) * 2020-12-14 2021-01-27 Heptares Therapeutics Ltd H4 antagonist comnpounds
WO2022203399A1 (en) * 2021-03-26 2022-09-29 주식회사 스탠다임 Adenosine a2a receptor antagonist and use thereof
EP4421067A1 (en) * 2021-10-19 2024-08-28 Unimatec Co., Ltd. Fluorine-containing pyrazole compound and production method therefor
KR102621694B1 (en) * 2022-09-15 2024-01-08 주식회사 스탠다임 Adenosine a2a receptor antagonist and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4800299A (en) * 1998-07-24 2000-02-14 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives and salts thereof
JP2000169475A (en) 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd Pyrazole derivative and salt thereof
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (en) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (en) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (en) 2007-12-19 2009-09-25 Palau Pharma Sa DERIVATIVES OF 2-AMINOPYRIMIDINE
SI2235012T1 (en) 2007-12-21 2013-11-29 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
JP5743897B2 (en) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Compound
TW201035078A (en) 2009-03-20 2010-10-01 Incyte Corp Substituted heterocyclic compounds
KR20120092141A (en) 2009-10-29 2012-08-20 서트리스 파마슈티컬즈, 인코포레이티드 Bicyclic pyridines and analogs as sirtuin modulators
RU2573828C2 (en) 2009-12-23 2016-01-27 Медисиз Фармасьютикал Корпорейшн Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
ES2620119T3 (en) 2012-11-16 2017-06-27 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
WO2018023029A1 (en) 2016-07-28 2018-02-01 Mayo Foundation For Medical Education And Research Small molecule activators of parkin enzyme function

Also Published As

Publication number Publication date
EP3867248A1 (en) 2021-08-25
JP2022507013A (en) 2022-01-18
US20250115587A1 (en) 2025-04-10
US12234227B2 (en) 2025-02-25
GB201817047D0 (en) 2018-12-05
US20210300906A1 (en) 2021-09-30
CN113272297A (en) 2021-08-17
KR20210079318A (en) 2021-06-29
CN113272297B (en) 2024-03-19
AU2019360428B2 (en) 2024-05-09
JP7532353B2 (en) 2024-08-13
MX2021004280A (en) 2021-05-31
AU2019360428A1 (en) 2021-04-29
WO2020079457A1 (en) 2020-04-23
CA3116628A1 (en) 2020-04-23
BR112021007372A2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
IL272056A (en) Heterocyclic compounds as adenosine antagonists
ZA202204675B (en) New methylquinazolinone derivatives
SG11202103133QA (en) Pyrazole derivatives as h4 antagonist compounds
IL279452B (en) Pyrazole derivatives as malt1 inhibitors
IL279453B (en) Pyrazole derivatives as malt1 inhibitors
IL289197A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
IL283990A (en) Substituted oxopyridine derivatives
IL284767A (en) Heterocyclic compounds as adenosine antagonists
EP3331532A4 (en) Substituted aminoquinazoline compounds as a2a antagonist
ZA201708611B (en) Pyrazole derivative, or pharmaceutically acceptable salt thereof
PL4077334T3 (en) Furoindazole derivatives
IL290815A (en) Alpha-d-galactopyranoside derivatives
IL279938A (en) Spirochromane derivatives
IL284762A (en) Heterocyclic compounds as adenosine antagonists
LT3796975T (en) Sulfonylaminobenzamide derivatives
IL310777A (en) Substituted s-alaninate derivatives
GB201919213D0 (en) Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
ZA201904313B (en) Heterocyclic derivatives as antibacterial compounds
HUE062256T2 (en) Dihydrochromene derivatives
HK40048587A (en) Pyrazole derivatives as h4 antagonist compounds
GB201918392D0 (en) H4 Antagonist compounds
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
GB201901868D0 (en) H4 antagonist compounds
HK40029095A (en) Heterocyclic compounds as adenosine antagonists